Hyaluronic Acid (HA) Conjugation of Anti-Cancer Drugs Increases Their Delivery and Efficacy
Section: For Industry
Categories: "Cancer Therapeutics"
Reference #: 2002-038
OTC Contact: Ruchika Nijhara, Ph.D. (Directory Information | Send a Message)
Description
Hyaluronic acid (HA) receptors are overexpressed on cancer cell surface. The present invention describes a targeted drug delivery system for cancer cells. Specifically, the invention relates to compounds composed of at least one residue of HA and at least one anti-cancer drug molecule for targeting the drug to cancer cells. Further, the invention is directed to methods of increasing the delivery and therapeutic efficacy of the drug by pre-administering a non HA glycoaminoglycans (GAGs) blocking agent before administering the HA conjugate.
Applications
- Cell-targeted delivery of anti-cancer drugs
Advantages
- Water-soluble
- Enhanced Permeability and retention of the drug
- Increased therapeutic index of the drug through receptor-mediated uptake by target cancer cells.
- Hyaluronic acid is an immunoneutral and also employed both as a vehicle and angiostatic agent in cancer therapy.
Stage of Development
Proof-of-concept demonstrated in animals.Relevant Publications
Lurong Zhang et al. Analysis of hyaluronan using biotinylated hyaluronan-Binding proteins. Methods in Mol. Biol. 2000;137:441-447
INVENTORS: Lurong Zhang, and Glenn Prestwich.
Patent Status
PCT/US2003/014087 entitled, “Preblocking with non-HA gags increases effectiveness of HA conjugated anticancer agents” filed on June 5, 2002. Patent pending in US, Europe and Australia.
